Centessa Pharmaceuticals Plc Stock Today
| CNTA Stock | USD 16.63 0.88 5.59% |
PerformanceVery Weak
| Odds Of DistressLow
|
Centessa Pharmaceuticals is trading at 16.63 as of the 25th of March 2025, a 5.59% increase since the beginning of the trading day. The stock's open price was 15.75. Centessa Pharmaceuticals has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of May 2021 | Category Healthcare | Classification Health Care |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Centessa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 133.18 M outstanding shares of which 4.15 M shares are currently shorted by private and institutional investors with about 5.46 trading days to cover. More on Centessa Pharmaceuticals PLC
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Centessa Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Program | Mario Accardi | ||||
| Thematic Ideas | (View all Themes) | ||||
| Old Name | Connecta AB | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Computers, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCentessa Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Centessa Pharmaceuticals' financial leverage. It provides some insight into what part of Centessa Pharmaceuticals' total assets is financed by creditors.
| |||||
Centessa Pharmaceuticals PLC (CNTA) is traded on NASDAQ Exchange in USA. It is located in 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT and employs 75 people. Centessa Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.21 B. Centessa Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 133.18 M outstanding shares of which 4.15 M shares are currently shorted by private and institutional investors with about 5.46 trading days to cover.
Centessa Pharmaceuticals PLC currently holds about 484.16 M in cash with (160.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.13.
Check Centessa Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCentessa Pharmaceuticals holds a total of 133.18 Million outstanding shares. The majority of Centessa Pharmaceuticals PLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Centessa Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Centessa Pharmaceuticals. Please pay attention to any change in the institutional holdings of Centessa Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Centessa Ownership Details
Centessa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Point72 Asset Management, L.p. | 2024-12-31 | 3.4 M | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 3.4 M | |
| Siren, L.l.c. | 2024-12-31 | 3 M | |
| Tcg Crossover Management, Llc | 2024-12-31 | 2.9 M | |
| Cormorant Asset Management, Llc | 2024-12-31 | 2.6 M | |
| Franklin Resources Inc | 2024-12-31 | 2.3 M | |
| Commodore Capital Lp | 2024-12-31 | 2.2 M | |
| Octagon Capital Advisors Lp | 2024-12-31 | 2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.9 M | |
| Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 20 M | |
| Index Venture Life Associates Vi Ltd | 2024-12-31 | 10 M |
Centessa Pharmaceuticals Historical Income Statement
Centessa Stock Against Markets
Centessa Pharmaceuticals Corporate Management
| Tia Bush | Chief Officer | Profile | |
| Ellie MD | Senior Oncology | Profile | |
| MD MSc | Ex Devel | Profile | |
| April Dovholuk | Senior Operations | Profile | |
| JD Esq | Senior Communications | Profile | |
| Charlene Stoudt | Senior Operations | Profile | |
| MBA MD | Principal CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.